病毒血症
血清转化
病毒载量
病毒学
抗体
病毒性疾病
抗原
免疫学
医学
人类免疫缺陷病毒(HIV)
HIV抗原
病毒复制
生物
病毒
作者
Eberhard Fiebig,David J. Wright,B. D. Rawal,Patricia E. Garrett,Richard Schumacher,Lorraine Peddada,Charles M. Heldebrant,Richard Smith,Andrew Conrad,Steven Kleinman,Michael P. Busch
出处
期刊:AIDS
[Lippincott Williams & Wilkins]
日期:2003-08-27
卷期号:17 (13): 1871-1879
被引量:1307
标识
DOI:10.1097/00002030-200309050-00005
摘要
OBJECTIVES: The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays. DESIGN: A retrospective study involving two sets of archived samples from HIV-infected plasma donors. (A) 435 samples from 51 donors detected by anti-HIV enzyme immunoassays donated during 1984-1994; (B) 145 specimens from 44 donors detected by p24 antigen screening donated during 1996-1998. SETTING: Two US plasma products companies. MAIN OUTCOME MEASURES: The timepoints of appearance of HIV-1 markers and viral load concentrations during primary HIV infection. RESULTS: The pattern of sequential emergence of viral markers in the 'A' panels was highly consistent, allowing the definition and estimation of the duration of six sequential stages. From the 'B' panels, the viral load at p24 antigen seroconversion was estimated by regression analysis at 10 000 copies/ml (95% CI 2000-93 000) and the HIV replication rate at 0.35 log copies/ml/day, corresponding to a doubling time in the preseroconversion phase of 20.5 h (95% CI 18.2-23.4 h). Consequently, an RNA test with 50 copies/ml sensitivity would detect HIV infection approximately 7 days before a p24 antigen test, and 12 days before a sensitive anti-HIV test. CONCLUSION: The sequential emergence of assay reactivity allows the classification of primary HIV-1 infection into distinct laboratory stages, which may facilitate the diagnosis of recent infection and stratification of patients enrolled in clinical trials. Quantitative analysis of preseroconversion replication rates of HIV is useful for projecting the yield and predictive value of assays targeting primary HIV infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI